Survey on controls for the presence of HBsAg in products based on hemoderivatives.
In Italy, Health Ministry provisions prohibit the marketing of products based on hemoderivatives unless they have first been controlled for the presence of HBsAg by means of radioimmunoassay. The present survey considers certificates submitted by Pharmaceutical Companies to the Health Department for permission to market their hemoderivative-based products. The results of the survey are discussed, and compared with the data obtained by the AA. in official control analyses, so as to arrive at some conclusion as to the applicability of currently employed RIA methods to HBsAg detection in hemoderivatives.
D000906:Antibodies / Q000032:analysis; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000032:analysis; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006801:Humans; D007106:Immune Sera / Q000592:standards*; D010949:Plasma / Q000382:microbiology*; D011863:Radioimmunoassay
D000906:Antibodies; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D007106:Immune Sera